 |
市場調查報告書
商品編碼
1518472
黏膜霧化設備市場- 產品類型（鼻霧化、光纖霧化、喉部氣管霧化、瓶式霧化器）、技術（氣體推進霧化、電霧化）、最終用戶- 全球預測（ 2024 - 2032）Mucosal Atomization Device Market - Product Type (Nasal Atomization, Fiber Optic Atomization, Laryngo Tracheal Atomization, Bottle Atomizers), Technology (Gas Propelled Atomization, Electrical Atomization), End User - Global Forecast (2024 - 2032) |
||||||
在慢性病盛行率日益上升的推動下，黏膜霧化裝置市場規模在 2024 年至 2032 年期間將以 7.4% 的複合年成長率成長。根據世界衛生組織的報告，每年因非傳染性疾病（NCD）死亡的比例已上升至總死亡人數的近四分之三。如果這一趨勢持續下去，預計到 2048 年全球這一比例將達到約 86%。
黏膜霧化裝置提供了一種非侵入性且便捷的給藥方式，具有快速吸收和提高患者依從性等優點。這些設備對於管理需要頻繁用藥的慢性病特別有價值，有助於更好的疾病管理和改善患者的治療效果。
先進的霧化技術包括改進噴嘴設計以實現更精確的藥物傳輸、納入劑量控制和監測的智慧功能以及開發攜帶式和方便用戶使用的設備。這些創新對於滿足各種醫療應用中對微創給藥方法日益成長的需求至關重要，從而塑造醫療保健服務的未來。
黏膜霧化裝置產業根據產品類型、技術、最終用戶和地區進行分類。
到2032年，喉部氣管霧化裝置領域將受到重視，因為它能夠將藥物直接輸送到喉部和氣管中，確保快速吸收和治療效果。 LTA 設備在急診醫學和重症監護病房 (ICU) 中特別有價值，在這些病房中，立即給藥對於患者穩定至關重要。 LTA 設備能夠準確有效地提供藥物，從而改善患者的治療效果，使其成為現代醫療保健環境中的重要工具。
氣體推進霧化裝置領域將在 2032 年之前快速成長，因為它們可確保均勻分佈並增強生物利用度。氣體推進霧化技術因其可靠性和多功能性而受到青睞，可用於輸送多種藥物，包括疫苗、抗生素和鎮痛藥。這些設備提供的劑量和粒徑的精確控制對於最佳化治療結果和減少治療時間至關重要。
在先進的醫療基礎設施和不斷採用創新醫療技術的推動下，歐洲黏膜霧化設備產業將在 2032 年之前穩定成長。德國、法國和英國等國家在強勁的醫療保健支出和有利的監管政策的支持下處於市場成長的前沿。慢性病盛行率的上升和人口老化進一步推動了對高效藥物輸送解決方案的需求。此外，正在進行的藥品和醫療設備研發活動促進了先進霧化設備在該地區的引進。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 呼吸道疾病盛行率上升
- 擴大鼻內給藥系統的採用
- 對更安全的藥物傳輸解決方案的需求激增
- 透過黏膜霧化裝置精確給藥
- 產業陷阱與挑戰
- 嚴格的法規核准程序
- 與不同類型藥物的相容性有限
- 成長動力
- 成長潛力分析
- 技術景觀
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 公司市佔率分析
- 競爭定位矩陣
- 戰略儀錶板
第 5 章：市場估計與預測：按產品類型，2021 - 2032 年
- 主要趨勢
- 鼻霧化裝置
- 光纖霧化裝置
- 喉氣管霧化裝置
- 瓶裝霧化器
第 6 章：市場估計與預測：按技術分類，2021 - 2032 年
- 主要趨勢
- 氣體推進霧化裝置
- 電霧化裝置
第 7 章：市場估計與預測：按最終用戶分類，2021 - 2032 年
- 主要趨勢
- 醫院
- 門診手術中心
- 專科診所
第 8 章：市場估計與預測：按地區，2021 - 2032
- 主要動向：按地區
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 日本
- 中國
- 印度
- 韓國
- 澳洲
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 阿拉伯聯合大公國
- 沙烏地阿拉伯
- 中東和非洲其他地區
第 9 章：公司簡介
- Becton, Dickinson and Co.
- BTME Group Ltd. (Medtree)
- BVM Meditech Pvt. Ltd.
- Cook Medical, Inc.
- DeVilbiss Healthcare LLC
- Intersurgical Ltd.
- Kurve Therapeutics
- Life-Assist Inc.
- Medica Holdings, LLC
- Medspray
- Pulmodyne, Inc.
- Teleflex Inc.
The Mucosal Atomization Device Market size will grow at 7.4% CAGR during 2024-2032, driven by the increasing prevalence of chronic diseases. According to the WHO report, the proportion of annual deaths attributed to non-communicable diseases (NCDs) has risen to nearly three-quarters of all deaths. If this trend persists, it is projected to reach approximately 86% worldwide by 2048.
Mucosal atomization devices provide a non-invasive and convenient way to administer medications, offering advantages such as rapid absorption and improved patient compliance. These devices are particularly valuable in managing chronic conditions that require frequent medication administration, contributing to better disease management and enhanced patient outcomes.
Advanced atomization technologies include improvements in nozzle design for more precise drug delivery, incorporation of smart features for dosage control and monitoring, and the development of portable and user-friendly devices. Such innovations are crucial in meeting the increasing demand for minimally invasive drug delivery methods across various medical applications, thereby shaping the future of healthcare delivery.
The mucosal atomization device industry is classified based on product type, technology, end-user and region.
The laryngo tracheal atomization devices segment will gain prominence through 2032, owing to its ability to deliver medications directly into the larynx and trachea, ensuring rapid absorption and therapeutic efficacy. LTA devices are particularly valuable in emergency medicine and intensive care units (ICUs) where immediate drug administration is crucial for patient stabilization. The ability of LTA devices to deliver medications accurately and efficiently enhances patient outcomes, making them essential tools in modern healthcare settings.
The gas propelled atomization devices segment will grow at a rapid pace through 2032, as they ensure uniform distribution and enhanced bioavailability. Gas propelled atomization technology is preferred for its reliability and versatility in delivering a wide range of medications, including vaccines, antibiotics, and analgesics. The precise control over dosage and particle size offered by these devices is critical in optimizing therapeutic outcomes and reducing treatment times.
Europe mucosal atomization device industry will grow at a steady pace through 2032, driven by advanced healthcare infrastructure and increasing adoption of innovative medical technologies. Countries like Germany, France, and the UK are at the forefront of market growth, supported by robust healthcare spending and favorable regulatory policies. The rising prevalence of chronic diseases and the aging population further fuel the demand for efficient drug delivery solutions. Moreover, ongoing R&D activities in pharmaceuticals and medical devices catalyze the introduction of advanced atomization devices in the region.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of respiratory illnesses
- 3.2.1.2 Expanding adoption of intranasal drug delivery systems
- 3.2.1.3 Surging demand for safer medication delivery solutions
- 3.2.1.4 Precise drug delivery through mucosal atomization devices
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Stringent regulatory approval procedures
- 3.2.2.2 Limited compatibility with different types of medications
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technology landscape
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Nasal atomization devices
- 5.3 Fiber optic atomization devices
- 5.4 Laryngo tracheal atomization devices
- 5.5 Bottle atomizers
Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Gas propelled atomization devices
- 6.3 Electrical atomization devices
Chapter 7 Market Estimates and Forecast, By End User, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Ambulatory surgery centers
- 7.4 Specialty clinics
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends, by region
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 South Korea
- 8.4.5 Australia
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 UAE
- 8.6.3 Saudi Arabia
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Becton, Dickinson and Co.
- 9.2 BTME Group Ltd. (Medtree)
- 9.3 BVM Meditech Pvt. Ltd.
- 9.4 Cook Medical, Inc.
- 9.5 DeVilbiss Healthcare LLC
- 9.6 Intersurgical Ltd.
- 9.7 Kurve Therapeutics
- 9.8 Life-Assist Inc.
- 9.9 Medica Holdings, LLC
- 9.10 Medspray
- 9.11 Pulmodyne, Inc.
- 9.12 Teleflex Inc.
